Elicio Therapeutics, Inc.
ELTX
$4.80
$0.040.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -11.77% | 14.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 30.28% | -5.31% | |||
| Operating Income | -30.28% | 5.31% | |||
| Income Before Tax | 25.66% | -160.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 25.66% | -160.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 25.66% | -160.59% | |||
| EBIT | -30.28% | 5.31% | |||
| EBITDA | -30.39% | 5.29% | |||
| EPS Basic | 26.03% | -116.50% | |||
| Normalized Basic EPS | 26.03% | -116.48% | |||
| EPS Diluted | 26.03% | -116.50% | |||
| Normalized Diluted EPS | 26.03% | -116.48% | |||
| Average Basic Shares Outstanding | 0.50% | 20.36% | |||
| Average Diluted Shares Outstanding | 0.50% | 20.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||